ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine ‐induced thrombotic microangiopathy
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 23, 2017 Category: Hematology Source Type: research
Paired comparison of therapeutic plasma exchange using the Fenwal Amicus versus TerumoBCT Spectra Optia
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 23, 2017 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 23, 2017 Category: Hematology Source Type: research
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine ‐induced thrombotic microangiopathy
We report the case of a 45‐year‐old female who presented with concern for a Category IV disorder, gemcitabine‐induced thrombotic microangiopathy, and was ultimately diagnosed with a Category I disorder, idiopathic thrombotic thrombocytopenic purpura. This case highlights the importance of ruling out idiopathic TTP by a thorough evaluation for ADAMTS13 activity and inhibitor, even when an alternate thrombotic microangiopathy diagnosis may be likely. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 23, 2017 Category: Hematology Authors: Peter G. Bittar, Myles S. Nickolich, Oluwatoyosi A. Onwuemene Tags: CASE REPORT Source Type: research
Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis
ConclusionTo our knowledge, we are reporting the first use of Therakos CELLEX and Spectra Optia PMN protocol for WBC depletion. While the Spectra Optia granulocyte protocol showed the best performance for this AML patient, further studies will be needed to compare the Spectra Optia PMN protocol to the MNC protocol for AML patients. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 22, 2017 Category: Hematology Authors: Abigail Cline, Ryan Jajosky, James Shikle, Roni Bollag Tags: BRIEF REPORT Source Type: research
The Barcelona Hospital Cl ínic therapeutic apheresis database
ConclusionThe TA database helped us to increase our knowledge about various indications and type of TA procedures that were performed in our current practice. We also believe that this database could serve as a model that other institutions can use to track service metrics. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 22, 2017 Category: Hematology Authors: Joan Cid, Gloria Carbass é, Marc Cid‐Caballero, Yolanda López‐Púa, Cristina Alba, Dolores Perea, Miguel Lozano Tags: RESEARCH ARTICLE Source Type: research
Comparing leukapheresis protocols for an AML patient with symptomatic leukostasis
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 22, 2017 Category: Hematology Source Type: research
The Barcelona Hospital Cl ínic therapeutic apheresis database
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 22, 2017 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 22, 2017 Category: Hematology Source Type: research
Stem cell mobilization in patients with dialysis ‐dependent multiple myeloma: Report of the polish multiple myeloma group
ConclusionsThe success rate in terms of obtaining sufficient number of CD34(+) cells/kg for an auto‐HSCT (≥2 × 106 cells/kg body weight) during the first mobilization attempt was 92% (26/28 patients), and for 2 auto‐HSCTs (≥4 × 106 cells/kg) – was 75% (21/28 patients). After the second mobilization attempt (undertaken in 8 patients), a sufficient number of CD34(+)/kg cells for an auto‐HSCT was obtained for all patients and the number of CD34(+)/kg collected cells was sufficient for 2 auto‐HSCT in 6 additional patients. Hematologic toxicity and infections were the most frequent complications. Higher doses of...
Source: Journal of Clinical Apheresis - September 18, 2017 Category: Hematology Authors: Anna Waszczuk ‐Gajda, Joanna Drozd‐Sokołowska, Piotr Boguradzki, Jarosław Dybko, Tomasz Wróbel, Grzegorz Władysław Basak, Krzysztof Mądry, Emilian Snarski, Grzegorz Charliński, Ewa Frączak, Joanna Matuszkiewicz‐Rowińska, Marian Klinger, Han Tags: RESEARCH ARTICLE Source Type: research
Stem cell mobilization in patients with dialysis ‐dependent multiple myeloma: Report of the Polish Myeloma Study Group
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 18, 2017 Category: Hematology Source Type: research
Therapeutic plasma exchange in the treatment of complicated Plasmodium falciparum malaria: A case report
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 18, 2017 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - September 18, 2017 Category: Hematology Source Type: research
